PRINCESS: Intermittent Fasting Versus Carbohydrate Drinks Before Surgery

Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05760339
Collaborator
European Society of Anaesthesiology and Intensive Care (Other)
75
1
3
11.1
6.8

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate whether intermittent fasting before surgery improves insulin resistance around the time of surgery, compared to carbohydrate drinks and standard fasting before surgery.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Time-restricted feeding
  • Dietary Supplement: Carbohydrate loading
N/A

Detailed Description

Patients in the TRF group will follow a daily TRF regimen consisting of an 8h ad libitum eating period and a 16h water fasting period during the last two weeks before surgery, followed by routine preoperative fasting before surgery.

Patients in the CHL group will follow their usual diet in the pre-surgical weeks and will receive a maltodextrin beverage on the evening before surgery, as well as two hours before induction of anaesthesia.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Preoperative Intermittent Fasting Versus Carbohydrate Loading to Reduce Insulin Resistance: a Randomised Controlled Trial
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Time-restricted feeding

Subjects will follow a daily time-restricted feeding regimen consisting of an 8h ad libitum eating period and a 16h water fasting period during the last two weeks before surgery, followed by routine preoperative fasting before surgery.

Behavioral: Time-restricted feeding
Subjects in the will be instructed to follow a TRF regimen consisting of a daily 8h ad libitum eating period and 16h water fasting period during the last 2 weeks before surgery. Participants will be encouraged to begin their eating period at 08:00h and end it at 16:00h, since the metabolic benefits of TRF appear to be considerably more pronounced when the eating period starts early in the day.

Active Comparator: Carbohydrate loading

Subjects will follow their usual diet in the pre-surgical weeks and will receive a maltodextrin beverage on the evening before surgery, as well as two hours before induction of anaesthesia

Dietary Supplement: Carbohydrate loading
Subjects will continue their usual diet and will receive two quantities of a clear beverage containing 12.5 g/100 mL maltodextrin (50 kCal/100 mL, pH 5.0); 800 mL at 22.00h on the evening before surgery and 400 mL two hours before anaesthesia induction.

No Intervention: Control group

Subjects will continue their usual diet and proceed with standard preoperative fasting (i.e., eat up until 6 hours and take clear liquids up until 2 hours before induction of anaesthesia).

Outcome Measures

Primary Outcome Measures

  1. Insulin resistance on postoperative day 1 [Postoperative day 1]

    Insulin resistance according to the homeostasis model assessment of insulin resistance (HOMA-IR)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Undergoing elective orthopaedic surgery;

  • Intermediate, major or complex surgery according to the Surgical Outcome Risk Tool (SORT; http://www.sortsurgery.com/) severity of surgery classification;

  • Scheduled for surgery at least 17 days from the date of screening;

  • Motivated to follow a time restricted feeding regimen.

  • Willing and able to provide written informed consent.

Exclusion Criteria:
  • History of diabetes mellitus;

  • History of feeding or eating disorders;

  • History of delayed gastric emptying or gastro-oesophageal reflux

  • Active malignancy

  • Patients classified as ASA IV by the attending anaesthetist;

  • BMI < 18.5 or ≥ 35;

  • Outpatient or day case surgery;

  • Palliative surgery;

  • Participation in another clinical trial that is interfering with the procedures or outcomes of the PRINCESS trial;

  • Patients unable to fully comply to study needs (e.g. legally incapable patients or patients unable to communicate in Dutch).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Amsterdam UMC location AMC Amsterdam Noord-Holland Netherlands 1105AZ

Sponsors and Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • European Society of Anaesthesiology and Intensive Care

Investigators

  • Principal Investigator: Jeroen Hermanides, MSc, Amsterdam UMC, location AMC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
B Preckel, Prof. Dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier:
NCT05760339
Other Study ID Numbers:
  • NL81556.018.22
First Posted:
Mar 8, 2023
Last Update Posted:
Mar 8, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by B Preckel, Prof. Dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2023